N/A N=24 Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation
Vasomotor Rhinitis
Primary: Net Proportional Change in Nasal Airway Resistance — 0.11; 0.04 proportional change (unit-less)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=352 Study Of Adults And Adolescents With Vasomotor Rhinitis
Rhinitis, Vasomotor
Primary: Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Score (rTNSS) — -1.71; -2.05 Score on scale — p=0.050
Phase 3 N=347 Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis
Vasomotor Rhinitis · Rhinitis, Vasomotor
Primary: Mean Change From Baseline in Daily Reflective Total Nasal Symptom Scores (rTNSS) — -2.11; -2.01 Score on a scale — p=0.604
Phase 4 N=129 Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis
Vasomotor Rhinitis
Primary: Mean Change in 2-week rTNSS From Baseline — 5.9; 6.5 Units on a scale
Phase 4 N=80 Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis
Non-allergic Rhinitis
Primary: Change in Visual Analogue Scale for Major Nasal Symptoms — 3.66; 4.29; 4.49; 5.6 score on a scale
Phase 2 N=22 Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis
Nonallergic Irritant Rhinitis
Primary: Change in Total Symptom Score — -5; 2 score on a scale
Phase 2 N=40 SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis
Rhinitis
Primary: Mean Total Symptom Score (TSS) Elicited by a 1 Hour (h) Cold Dry Air (CDA) Challenge, 1 h and 24 h on Day 14 to Compare the Effect of 14 Day Repeat Dosing of Intranasal…
Phase 4 N=50 Effectiveness of Oxymetazoline Added on Nasal Steroid in Rhinitis With Persistent Nasal Obstruction
Nasal Obstruction Present Finding
Primary: Effectiveness of Oxymetazoline in the Treatment of Rhinitis With Persistent Nasal Obstruction — 1.38; 1.67 units on a scale
Phase 4 N=64 Intranasal Steroids and Oxymetazoline in Allergic Rhinitis
Allergic Rhinitis
Primary: Total Nasal Congestion Symptom Score — 94; 70; 75; 68 units on a scale
N/A N=50 Posterior Nasal Nerve (PNN) Rhinitis Study
Chronic Rhinitis
Primary: Change in Reflective Total Nasal Symptom Score (rTNSS) — -5.1 units on a scale — p=<0.0001
Phase 3 N=28 The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population
Non-allergic Rhinitis
Primary: Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline — 6.07 score on a scale
Phase 2 N=21 A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge
Allergic Rhinitis
Primary: Minimum Cross-Sectional Area (Amin) Proportion Measured Using Acoustic Rhinometry — 0.760; 0.742; 0.717; 0.795 ratio — p=0.302
Phase 2 N=617 Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) Twice Daily Averaged Subject-rated Reflective Total Nasal Symptom Score (TNSS) — -1.19; -1.58; -1.68; -1.63 score on a scale
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Phase 2 N=126 Herbal Treatment for Perennial Allergic Rhinitis
Perennial Allergic Rhinitis
Primary: Allergic Rhinitis Symptom Score Including Rhinorrhea, Nasal Obstruction, Sneezing, Itchy Nose and Itchy Eyes at Week 4 — 2.82; 2.8; 1.19; 1.21 Unit Score
N/A N=43 Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial
Vasomotor Rhinitis
Primary: Total Nasal Symptom Scores — 3.0; 3.1 score on a scale — p=0.45
N/A N=30 Multi-Treatment PNN Modulation for Chronic Rhinitis
Chronic Rhinitis
Primary: Number of Participants With Procedure-related Serious Adverse Events (SAEs) and/or Serious Adverse Device Effects (SADE) — 0 Participants
Phase 4 N=21 Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms
Seasonal Allergic Rhinitis
Primary: Total Eye Symptoms Score Difference — 6; 0; 2.5; 1.5 units on a scale — p=<0.001
N/A N=300 Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary
Rhinitis
Primary: The Change From Baseline in the Mean of the 3 Single Symptom Scores (Blocked Nose, Sneezing and Running Nose) at the Closing/Final Visit. — -2 units on a scale
Phase 3 N=327 Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
Perennial Allergic Rhinitis
Primary: Total Preference Composite Score Assessed at the End of the Study. The Total Preference Score is the Standardized Sum of 17 Individual Preference Items — 68.3 scores on…
Phase 2 N=606 Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline (Pre-Dose) in Morning and Evening Averaged Subject-rated Reflective TNSS — -3.57; -2.31; -2.96; -1.48 score on a scale
Phase 4 N=130 Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial
Seasonal Allergic Rhinitis
Primary: Mean Percent Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline — -45.37; -47.35 Percent change
Phase 2 N=102 A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline in Daily rTNSS Over the Entire Treatment Period (28 Days) — -2.10; -2.17 points on a scale — p=0.845
Phase 3 N=351 A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
Perennial Allergic Rhinitis
Primary: Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks — 7.84; 8.41; 8.27; 8.29 Units on a scale — p=0.0001
N/A N=13 Intranasal CO2 for Allergic Rhinitis
Allergic Rhinitis
Primary: Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge — 6; 19.6 milligrams
Phase 3 N=340 Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
Seasonal Allergic Rhinitis · Hay Fever
Primary: Change From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period — -2.0; -1.0 units on a scale…
N/A N=10 Acupuncture for Nasal Congestion in Allergic Rhinitis
Allergic Rhinitis
Primary: Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value) — -8; -2 Scale points
Phase 2 N=70 Intranasal SB-705498 in Allergic Rhinitis (AR) Patients
Rhinitis
Primary: Mean Total Nasal Symptom Score (TNSS) and Its Individual Components on Day 8 — 6.53; 3.65; 6.57; 4.14 Score on scale
Phase 3 N=333 Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)
Allergic Rhinitis
Primary: Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days — -0.71; -0.40 Units on a scale — p=<0.001
Phase 2 N=707 Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)
Seasonal Allergic Rhinitis
Primary: Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15 — -3.29; -3.36; -2.97; -2.44 units on a scale — p=0.002